Lemalesomab
Lemalesomab (IMMU-MN3) is a Fab' fragment of a murine anti-granulocyte monoclonal antibody targeting NCA-90 (CEACAM6). Lemalesomab binds strongly to NCA-90 on the surface of granulocytes, cross-reacts with epitopes of other CEA family members, and blocks the binding between human colon adenocarcinoma cells and CEA. When labeled with 99mTc, Lemalesomab can be used for radionuclide imaging of soft tissue infections and osteomyelitis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 250242-54-7
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Human IgG1 kappa
Human
NCA-90
Pre-incubation of purified human neutrophils with Lemalesomab (20 μg/mL; 30 min) does not impair granulocyte functions (superoxide anion production, phagocytosis, chemotaxis, or MTT reduction), and a small but significant increase in MTT reduction is observed upon fMLP stimulation[1].
Lemalesomab inhibits the binding between the KM-12c human colon adenocarcinoma cell line and CEA by 80%-90%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS. Nr. 250242-54-7
-
SMILES
[Lemalesomab]
-
Synonyms
IMMU-MN3
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)